COVID-19 vaccine efficacy data: solid enough to delay second dose?doi:10.1016/S0140-6736(21)01046-1John F R Robertson aHerb F Sewell aThe Lancet
optimistic, and promising statements by President Trump, to a concern that vaccines may be approved without sufficient safety and efficacy data from the media, politicians, and scientists. Key talking points included: stories of prior failed vaccine products, ...
“I think we really need to see more comprehensive documentation before making any assessment of the vaccine performance” says Cowling. “What we have seen so far is pretty limited information.” It’s not just the new efficacy figure in Brazil and the lack of public data that’s stirring ...
MD, PhD,director of the Applied Clinical Research Center and PEDSnet at The Children’s Hospital of Philadelphia, told Healio. “We knew that the vaccine had had good efficacy against the delta virus, but there was
In conclusion, receiving two doses of a COVID-19 vaccine was associated with lower odds of mortality and hospitalization and higher odds of infection. More research is needed to evaluate the safety and efficacy of vaccines against SARS-CoV-2....
However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we ...
Except for their efficacy, what about the safety of the two vaccines? The AZD1222 vaccine by Oxford and AstraZeneca combines a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and the genetic material of the SARS-CoV-2 virus. ...
AstraZeneca said additional analysis of the vaccine data could alter the results regarding its average efficacy, and help to establish the duration of the protection. Pascal Soriot, CEO of AstraZeneca, said the development marked an "important milestone" in the fight against the global health crisi...
Timely evaluation of the protective effects of Coronavirus Disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern is urgently needed to inform pandemic control planning. Based on 78 vaccine efficacy or effectiveness (VE) data from ...
Importantly, however, the majority of vaccine efficacy trials – including the Pfizer and Moderna vaccines approved in Canada and many other countries – have reported limited results related to efficacy among people over 70 years and data on people over 80 years is almost completely lacking [2],...